Aims. To investigate the impact of blood type, functional polymorphism ( @entity68129 ) of the COX-1 gene promoter, and clinical factors on the development of peptic @entity1066 during cardiovascular prophylaxis with low-dose @entity117 . Methods. In a case-control study including 111 low-dose @entity117 users with peptic ulcers and 109 controls (asymptomatic @entity117 users), the polymorphism ( @entity68129 ) of the COX-1 gene promoter was genotyped, and blood type, @entity1534 status, and clinical factors were assessed. Results. Univariate analysis showed no significant differences in genotype frequencies of the COX-1 gene at position -1676 between the peptic @entity1066 group and control group. Multivariate analysis revealed that blood type O, advanced age, history of peptic @entity1066 , and concomitant use of NSAID were the independent risk factors for the development of peptic @entity1066 with the odds ratios of the 2.1, 3.1, 27.6, and 2.9, respectively. Conclusion. The @entity68130 polymorphism in the COX-1 gene promoter is not a risk factor for @entity1066 formation during treatment with low-dose @entity117 . Blood type O, advanced age, history of peptic @entity1066 , and concomitant use of NSAID are of independent significance in predicting peptic @entity1066 development during treatment with low-dose @entity117 .

Impact of Blood Type, Functional Polymorphism ( XXXX ) of the COX-1 Gene Promoter and Clinical Factors on the Development of Peptic Ulcer during Cardiovascular Prophylaxis with Low-Dose @entity117 .

@entity117 :: ('MESH:D001241', 'Chemical') :: ['aspirin'] @entity1066 :: ('MESH:D014456', 'Disease') :: ['ulcer'] @entity68129 :: ('c|SUB|T|-1676|C', 'DNAMutation') :: ['T-1676C'] @entity1534 :: ('210', 'Species') :: ['H pylori'] @entity68130 :: ('c|SUB|C|-1676|T', 'DNAMutation') :: ['C-1676T']
@entity68129 :: (c|SUB|T|-1676|C,DNAMutation) :: ['T-1676C']
